BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

...study received steroids. Novaferon is a pegylated IFNα product from Genova...
...the proportion of patients virus-negative at day six.Genova did...
...Pegylated Interferon Lambda) Traumakine (FP-1201, FP-1201-lyo, MR11A8) Rebif, interferon beta-1a Genova...
BioCentury | May 16, 2018
Distillery Therapeutics

Pulmonary

...of Bologna Alma Mater Studiorum, Bologna, Italy email: andrea.cavalli@unibo.it CONTACT: Nicoletta Pedemonte, Giannina Gaslini Institute, Genova...
BioCentury | Dec 8, 2017
Financial News

Tasly unit invests $50M in Chinese diabetes play Genova

...advisor China Renaissance, the investment is part of Genova’s series B round. Founded in 2014, Genova...
...& Healthcare Construction and Development Co. Ltd. Genova could not be reached for comment. Allison Johnson insulin glargine Genova...
BioCentury | Sep 20, 2012
Targets & Mechanisms

Stabilizing RyR2

...la Sante et de la Recherche Medicale , Paris, France Italian Institute of Technology , Genova...
BioCentury | Mar 11, 2010
Distillery Therapeutics

Indication: Cancer

...University of Pisa, Pisa, Italy e-mail: aros@farm.unipi.it Contact: Marina Fabbi, National Institute of Cancer Research, Genova...
BioCentury | Sep 28, 2009
Company News

Bridge Bioresearch, GENova, Suncheon Cheongam College deal

...research on their respective programs. Further details were not disclosed (see BioCentury, Sept. 21). Separately, GENova...
...a letter of intent for exclusive rights to the college's IP covering cancer stem cells. GENova...
...to treat breast cancer. Further terms were not disclosed. Bridge Bioresearch plc , London, U.K. GENova Biotherapeutics Inc....
BioCentury | Sep 21, 2009
Company News

GENova, Bridge Bioresearch, Prime BioResearch deal

...GENova will acquire three patents covering undisclosed targets from an undisclosed company. GENova is developing tetanolic...
...treat breast cancer, with other compounds to treat prostate cancer. Also, in two separate deals, GENova...
...is focused on Type II diabetes, obesity and cardiovascular disorders. Further terms were not disclosed. GENova Biotherapeutics Inc....
BioCentury | Aug 24, 2009
Company News

GENova management update

GENova Biotherapeutics Inc. (OTCBB:GVBP), New York, N.Y. Business: Cancer, Infectious Hired: Aaron Whiteman as CEO, formerly VP at Reliance Biotech Pvt. Ltd. WIR Staff...
BioCentury | Jul 16, 2009
Distillery Therapeutics

Indication: Neurology

...J. Med. Chem.; published online June 23, 2009; doi:10.1021/jm900225j Contact: Fabio Sparatore, University of Genova, Genova...
BioCentury | Jun 5, 2008
Distillery Therapeutics

This Week in Therapeutics

...et al. Blood; published online May 12, 2008; doi:10.1182/blood-2008-02-139378 Contact: Irma Airoldi, G. Gaslini Institute, Genova...
Items per page:
1 - 10 of 12
BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

...study received steroids. Novaferon is a pegylated IFNα product from Genova...
...the proportion of patients virus-negative at day six.Genova did...
...Pegylated Interferon Lambda) Traumakine (FP-1201, FP-1201-lyo, MR11A8) Rebif, interferon beta-1a Genova...
BioCentury | May 16, 2018
Distillery Therapeutics

Pulmonary

...of Bologna Alma Mater Studiorum, Bologna, Italy email: andrea.cavalli@unibo.it CONTACT: Nicoletta Pedemonte, Giannina Gaslini Institute, Genova...
BioCentury | Dec 8, 2017
Financial News

Tasly unit invests $50M in Chinese diabetes play Genova

...advisor China Renaissance, the investment is part of Genova’s series B round. Founded in 2014, Genova...
...& Healthcare Construction and Development Co. Ltd. Genova could not be reached for comment. Allison Johnson insulin glargine Genova...
BioCentury | Sep 20, 2012
Targets & Mechanisms

Stabilizing RyR2

...la Sante et de la Recherche Medicale , Paris, France Italian Institute of Technology , Genova...
BioCentury | Mar 11, 2010
Distillery Therapeutics

Indication: Cancer

...University of Pisa, Pisa, Italy e-mail: aros@farm.unipi.it Contact: Marina Fabbi, National Institute of Cancer Research, Genova...
BioCentury | Sep 28, 2009
Company News

Bridge Bioresearch, GENova, Suncheon Cheongam College deal

...research on their respective programs. Further details were not disclosed (see BioCentury, Sept. 21). Separately, GENova...
...a letter of intent for exclusive rights to the college's IP covering cancer stem cells. GENova...
...to treat breast cancer. Further terms were not disclosed. Bridge Bioresearch plc , London, U.K. GENova Biotherapeutics Inc....
BioCentury | Sep 21, 2009
Company News

GENova, Bridge Bioresearch, Prime BioResearch deal

...GENova will acquire three patents covering undisclosed targets from an undisclosed company. GENova is developing tetanolic...
...treat breast cancer, with other compounds to treat prostate cancer. Also, in two separate deals, GENova...
...is focused on Type II diabetes, obesity and cardiovascular disorders. Further terms were not disclosed. GENova Biotherapeutics Inc....
BioCentury | Aug 24, 2009
Company News

GENova management update

GENova Biotherapeutics Inc. (OTCBB:GVBP), New York, N.Y. Business: Cancer, Infectious Hired: Aaron Whiteman as CEO, formerly VP at Reliance Biotech Pvt. Ltd. WIR Staff...
BioCentury | Jul 16, 2009
Distillery Therapeutics

Indication: Neurology

...J. Med. Chem.; published online June 23, 2009; doi:10.1021/jm900225j Contact: Fabio Sparatore, University of Genova, Genova...
BioCentury | Jun 5, 2008
Distillery Therapeutics

This Week in Therapeutics

...et al. Blood; published online May 12, 2008; doi:10.1182/blood-2008-02-139378 Contact: Irma Airoldi, G. Gaslini Institute, Genova...
Items per page:
1 - 10 of 12